Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 19, 2026, 2:09 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 407 matching trials from the live ClinicalTrials.gov search.
Conditions
Stage IIA Non-small Cell Lung Cancer, Stage IIB Non-small Cell Lung Cancer, Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer
Interventions
stereotactic body radiation therapy, carboplatin, paclitaxel, radiation therapy
Radiation · Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 80 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2022
U.S. locations
4
States / cities
Atlanta, Georgia • St Louis, Missouri
Conditions
Lung Cancer, Pulmonary Complications
Interventions
educational intervention, supervised exercise program
Other
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
Not listed
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
60
States / cities
Fort Collins, Colorado • Decatur, Illinois • Maywood, Illinois + 32 more
Conditions
Stage I Colon Cancer, Stage I Rectal Cancer, Stage IA Non-small Cell Lung Cancer, Stage IB Non-small Cell Lung Cancer, Stage IIA Colon Cancer, Stage IIA Non-small Cell Lung Cancer, Stage IIA Rectal Cancer, Stage IIB Colon Cancer, Stage IIB Non-small Cell Lung Cancer, Stage IIB Rectal Cancer, Stage IIC Colon Cancer, Stage IIC Rectal Cancer, Stage IIIA Colon Cancer, Stage IIIA Non-small Cell Lung Cancer, Stage IIIA Rectal Cancer, Stage IIIB Colon Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IIIB Rectal Cancer, Stage IIIC Colon Cancer, Stage IIIC Rectal Cancer
Interventions
educational intervention, questionnaire administration, quality-of-life assessment
Other · Procedure
Lead sponsor
City of Hope Medical Center
Other
Eligibility
21 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
Duarte, California
Conditions
Lung Cancer
Interventions
carboplatin, erlotinib hydrochloride, paclitaxel
Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years to 120 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
124
States / cities
Little Rock, Arkansas • Antioch, California • Berkeley, California + 90 more
Conditions
Adenocarcinoma of the Lung, Adenosquamous Cell Lung Cancer, Large Cell Lung Cancer, Squamous Cell Lung Cancer, Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer
Interventions
shark cartilage extract AE-941, placebo, cisplatin, vinorelbine tartrate, carboplatin, paclitaxel, radiation therapy
Drug · Other · Radiation
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
756 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
1
States / cities
Houston, Texas
Conditions
Lung Cancer, Metastatic Cancer
Interventions
chemotherapy, porfimer sodium, immunohistochemistry staining method, laboratory biomarker analysis, spectroscopy, therapeutic conventional surgery
Drug · Other · Procedure
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years to 120 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2012
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Lung Cancer
Interventions
oxaliplatin, paclitaxel
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2003
U.S. locations
11
States / cities
Chicago, Illinois • Decatur, Illinois • Evanston, Illinois + 6 more
Conditions
Lung Cancer
Interventions
carboplatin, irinotecan hydrochloride, thalidomide
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 120 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2004
U.S. locations
5
States / cities
Decatur, Illinois • Goldsboro, North Carolina • Winston-Salem, North Carolina + 2 more
Conditions
Carcinoma, Non-Small-Cell Lung, Non-Small Cell Lung Cancer
Interventions
CC-223, erlotinib, CC-223, oral azacitidine
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
7
States / cities
Los Angeles, California • San Francisco, California • New York, New York + 4 more
Conditions
Lung Cancer
Interventions
Trastuzumab, Cisplatin, Gemcitabine Hydrochloride
Biological · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2004
U.S. locations
1
States / cities
Houston, Texas
Conditions
Bladder Cancer, Breast Cancer, Colorectal Cancer, Lung Cancer, Ovarian Cancer, Pancreatic Cancer
Interventions
LMB-9 immunotoxin
Biological
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2003
U.S. locations
2
States / cities
Baltimore, Maryland • Bethesda, Maryland
Conditions
Caregiver, Psychological Impact of Cancer and Its Treatment, Recurrent Non-small Cell Lung Cancer, Stage IIA Non-small Cell Lung Cancer, Stage IIB Non-small Cell Lung Cancer, Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
Interventions
Palliative Therapy, quality-of-life assessment, questionnaire administration
Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
361 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
5
States / cities
Duarte, California • Irvine, California • Ontario, California + 2 more
Conditions
Non Small Cell Lung Cancer, Lung Cancer, Stage IIIA Non Small Cell Lung Cancer, Stage IIIB Non Small Cell Lung Cancer
Interventions
S-3304, Chemo-irradiation
Drug · Other
Lead sponsor
Shionogi
Industry
Eligibility
18 Years to 85 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
5
States / cities
La Jolla, California • Washington D.C., District of Columbia • Kansas City, Kansas + 2 more
Conditions
Advanced Adult Primary Liver Cancer, Carcinoma of the Appendix, Fallopian Tube Cancer, Gastrointestinal Stromal Tumor, Localized Extrahepatic Bile Duct Cancer, Localized Gallbladder Cancer, Localized Gastrointestinal Carcinoid Tumor, Localized Resectable Adult Primary Liver Cancer, Localized Unresectable Adult Primary Liver Cancer, Metastatic Gastrointestinal Carcinoid Tumor, Ovarian Sarcoma, Ovarian Stromal Cancer, Primary Peritoneal Cavity Cancer, Recurrent Adult Primary Liver Cancer, Recurrent Adult Soft Tissue Sarcoma, Recurrent Colon Cancer, Recurrent Extrahepatic Bile Duct Cancer, Recurrent Gallbladder Cancer, Recurrent Gastric Cancer, Recurrent Gastrointestinal Carcinoid Tumor, Recurrent Non-small Cell Lung Cancer, Recurrent Ovarian Epithelial Cancer, Recurrent Ovarian Germ Cell Tumor, Recurrent Pancreatic Cancer, Recurrent Rectal Cancer, Recurrent Small Intestine Cancer, Recurrent Uterine Sarcoma, Regional Gastrointestinal Carcinoid Tumor, Small Intestine Adenocarcinoma, Small Intestine Leiomyosarcoma, Small Intestine Lymphoma, Stage 0 Non-small Cell Lung Cancer, Stage I Adult Soft Tissue Sarcoma, Stage I Colon Cancer, Stage I Gastric Cancer, Stage I Non-small Cell Lung Cancer, Stage I Ovarian Epithelial Cancer, Stage I Ovarian Germ Cell Tumor, Stage I Pancreatic Cancer, Stage I Rectal Cancer, Stage I Uterine Sarcoma, Stage II Adult Soft Tissue Sarcoma, Stage II Colon Cancer, Stage II Gastric Cancer, Stage II Non-small Cell Lung Cancer, Stage II Ovarian Epithelial Cancer, Stage II Ovarian Germ Cell Tumor, Stage II Pancreatic Cancer, Stage II Rectal Cancer, Stage II Uterine Sarcoma, Stage III Adult Soft Tissue Sarcoma, Stage III Colon Cancer, Stage III Gastric Cancer, Stage III Ovarian Epithelial Cancer, Stage III Ovarian Germ Cell Tumor, Stage III Pancreatic Cancer, Stage III Rectal Cancer, Stage III Uterine Sarcoma, Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Adult Soft Tissue Sarcoma, Stage IV Colon Cancer, Stage IV Gastric Cancer, Stage IV Non-small Cell Lung Cancer, Stage IV Ovarian Epithelial Cancer, Stage IV Ovarian Germ Cell Tumor, Stage IV Pancreatic Cancer, Stage IV Rectal Cancer, Stage IV Uterine Sarcoma, Unresectable Extrahepatic Bile Duct Cancer, Unresectable Gallbladder Cancer
Interventions
EF5, motexafin lutetium, pharmacological study
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Recurrent Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
Interventions
gamma-secretase/Notch signalling pathway inhibitor RO4929097, laboratory biomarker analysis, pharmacological study
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Houston, Texas
Conditions
Lung Cancer
Interventions
carboplatin, paclitaxel, paclitaxel poliglumex
Drug
Lead sponsor
CTI BioPharma
Industry
Eligibility
18 Years to 120 Years · Female only
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
41
States / cities
Scottsdale, Arizona • Burbank, California • Escondido, California + 36 more
Conditions
Lung Cancer
Interventions
cisplatin, docetaxel
Drug
Lead sponsor
University of Medicine and Dentistry of New Jersey
Other
Eligibility
18 Years to 120 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2010
U.S. locations
13
States / cities
East Brunswick, New Jersey • Edison, New Jersey • Freehold, New Jersey + 9 more
Conditions
Lung Cancer
Interventions
docetaxel, gefitinib, laboratory biomarker analysis, radiation therapy
Drug · Other · Radiation
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 120 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2010
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Conditions
Metastatic Neoplasm, Recurrent Neoplasm, Recurrent Non-Small Cell Lung Carcinoma, Stage IIIA Non-Small Cell Lung Cancer, Stage IIIB Non-Small Cell Lung Cancer, Stage IV Non-Small Cell Lung Cancer, Unresectable Malignant Neoplasm
Interventions
Laboratory Biomarker Analysis, Quality-of-Life Assessment, Targeted Therapy
Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Conditions
Lung Cancer
Interventions
carboplatin, vinorelbine ditartrate
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2002
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Lung Cancer
Interventions
PF-00299804, Placebo
Drug
Lead sponsor
NCIC Clinical Trials Group
Network
Eligibility
18 Years and older
Enrollment
720 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
2
States / cities
Arcadia, California • Skokie, Illinois
Conditions
Recurrent Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
Interventions
erlotinib hydrochloride, celecoxib, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2010
U.S. locations
1
States / cities
Durham, North Carolina
Conditions
Lung Cancer
Interventions
selenomethionine, carboplatin, paclitaxel, laboratory biomarker analysis, radiation therapy
Dietary Supplement · Drug · Other + 1 more
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years to 120 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Buffalo, New York
Conditions
Lung Cancer, Metastatic Cancer
Interventions
3'-deoxy-3'-[18F]FLT, Single photon emission computed tomography
Other · Procedure
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Detroit, Michigan